279 related articles for article (PubMed ID: 29673110)
1. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
4. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
5. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
Beer A; Taghizadeh H; Schiefer AI; Puhr HC; Karner AK; Jomrich G; Schoppmann SF; Kain R; Preusser M; Ilhan-Mutlu A
Pathol Oncol Res; 2020 Oct; 26(4):2225-2235. PubMed ID: 32372174
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
[TBL] [Abstract][Full Text] [Related]
11. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status.
Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
17. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
19. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
